Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Zacks News
Renal Cell Carcinoma Space in Focus: Some Key Developments
by Ekta Bagri
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.
Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.
Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 8.70% and 5.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.
New Strong Buy Stocks for July 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
by Zacks Equity Research
Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.
Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
by Swarup Gupta
The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
by Zacks Equity Research
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
Exelixis (EXEL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 12.50% and 5.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
by Zacks Equity Research
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
by Zacks Equity Research
Exelixis (EXEL) performance has been impressive so far in 2019 on the back of label expansion of Cabometyx.
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
Biotech Stocks Outperform During Inversions: 5 Must Watch
by Tirthankar Chakraborty
An inverted yield curve signals a recession but it is often bullish for biotech stocks.
Exelixis (EXEL) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Exelixis (EXEL) closed at $24.76 in the latest trading session, marking a +0.2% move from the prior day.
Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.